Symposium Overview

Meeting Goals/Purpose

This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

The scientific program consists of formal lectures by experts in clinical, translational, and basic research, selected slide and poster presentations, forums and case discussions. The official language of the symposium is English. Simultaneous translation is not provided

Target Audience

This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals. We anticipate 10,000+ attendees from more than 102 countries.

Meeting Location

We are very pleased to announce that the San Antonio Breast Cancer Symposium® will take place in 2024. The Symposium offers attendees the unique opportunity to participate in person in San Antonio, Texas or virtually. The dates will be December 10-13, at the Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 USA.

Preliminary Schedule

The Preliminary Schedule is now available, click here for more information. 

Executive Committee

Carlos L. Arteaga, UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX, Co-Director
Virginia G. Kaklamani, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Co-Director
 
David Gius, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Dean Post, American Association for Cancer Research, Philadelphia, PA (ex-officio)
Kate Lathrop, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX (ex-officio)
Mark Bonnen, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Margaret Foti, American Association for Cancer Research, Philadelphia, PA

Program Planning Committee

Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Carey Anders, Duke Cancer Institute, Durham, NC
Fabrice Andre, Gustave Roussy, Ile de France, France
Carlos L. Arteaga, UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX
Justin Balko, Vanderbilt University, Nashville, TN
Andrea Barrio, Memorial Sloan Kettering Cancer Center, New York, NY
Mark Bonnen, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Thelma Brown, University of Alabama at Birmingham, Birmingham, AL
Carlos Caldás, University of Cambridge, Cambridge, United Kingdom
Suzanne Conzen, UT Southwestern Medical Center, Dallas, TX
Christina Curtis, Stanford University, Stanford, CA
Carol J. Fabian, University of Kansas Medical Center, Kansas City, KS
Margaret Foti, American Association for Cancer Research, Philadelphia, PA
David Gius, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia
Virginia G. Kaklamani, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Kate Lathrop, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX (ex-officio)
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia
Julia Maues, GRASP, Washington, DC
Heather McArthur, UT Southwestern Medical Center, Dallas, TX
Ann Partridge, Dana-Farber Cancer Institute, Boston, MA
Debra Patt, Texas Oncology, Austin, TX
Charles M. Perou, University of North Carolina, Chapel Hill, NC
Manjeet Rao, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, NY
Mothaffar Rimawi, Baylor College of Medicine, Houston, TX
Kalliopi Siziopikou, Northwestern University, Chicago, IL
Melinda Telli, Stanford University School of Medicine, Stanford, CA
Neil Vasan, Columbia University Irving Medical Center, New York, NY
Antonio Wolff, Johns Hopkins University, Baltimore, MD
Richard Zellars, Indiana University School of Medicine, Indianapolis, IN

Financial Disclosure Information

As an ACCME-accredited CME provider, UT Health Science Center San Antonio® must ensure that its CME activities are independent of the control of commercial interests. All speakers and planning committee members for the UT Health Science Center San Antonio sponsored programs are expected to disclose (prior to the activity) all “financial relationships” in any amount occurring within the past 24 months. Disclosures are then reviewed to identify any "relevant" financial relationships that create a conflict of interest. (“Relevant” financial interest or other relationships can include such things as grant or research support, employees, consultants, major stockholders, members of speaker bureau, etc.)

The UT Health Science Center San Antonio and a planner of SABCS® 2024 with no financial relationships with ineligible companies will review all financial disclosure information for all speakers, facilitators, and planning committee members; and determine and resolve all conflicts of interests.

All financial relationships have been reviewed and mitigated.

Certificate of Credit & Certificate of Attendance

To claim credits for the 2023 San Antonio Breast Cancer Symposium®, you must complete the session evaluations and the overall program evaluation. After you have claimed your credits, you will be able to download your certificate of credit and/or certificate of attendance.

Surveys are now closed as of, January 31, 2024, at 11:59 p.m.

For more information please contact the CME Office at cme@uthscsa.edu

If you do not need to claim credit but need proof of attendance, you will still need to complete the overall program evaluation. You will then be able to download your certificate. 

Accreditation 

The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

The UT Health San Antonio School of Medicine designates this live activity up to a maximum of 70.50 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for 70 contact hours.  

Maintenance of Certification



Successful completion of this CME activity, which includes participation in the evaluation component and self-assessment requirements, enables the participant to earn Maintenance of Certification (MOC) II points in the American Board of Internal Medicine’s (ABIM), American Board of Surgery’s Continuous Certification (ABS), American Board of Pediatrics (ABP), and the American Board of Pathology (ABPath) program. If you are board certified in these boards, please fill out the MOC II self-assessment. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting MOC II credit. Last day to submit for MOC II credit is January 31, 2024

Advocate Financial Assistance

Patient advocates wishing to apply for financial assistance for the 2024 SABCS® should contact the Alamo Breast Cancer Foundation for information and an application. Applications are available online. Please see their website for more information and qualifications.

Email: info@alamobreastcancer.org

Web: www.alamobreastcancer.org

Awards

The William L. McGuire Memorial Lectureship

Dr. William L. McGuire, along with Dr. Charles A. Coltman, founded the San Antonio Breast Cancer Symposium® in 1977. The William L. McGuire Memorial Lectureship was established in 1992 to commemorate the significant contributions of Dr. McGuire to oncology medicine. His research played a major role in introducing estrogen receptor assays on breast tumor tissue as a guide to treatment decisions for women with breast cancer. Breast cancer patients everywhere now receive these tests.

The lecturer is selected by the SABCS®​​​​​​​ McGuire Award Committee from persons through a nomination process. The selection is based on the following criteria:

• Lecturers are respected figures with an international reputation.

• They have made significant contributions to the field of breast cancer research.

• They are known as skilled presenters.

• They present a topic of high current interest related to the diagnosis and treatment of breast cancer or to the study of its underlying mechanisms.

AACR Outstanding Investigator Award for Breast Cancer Research, funded by The Breast Cancer Research Foundation

The AACR Outstanding Investigator Award for Breast Cancer Research is presented to an investigator no more than 50 years of age whose novel and significant work that has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer.

AACR Distinguished Lectureship in Breast Cancer Research

The AACR Distinguished Lectureship in Breast Cancer Research has been established to recognize outstanding science that has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment, or prevention of breast cancer.

Embargo

Abstracts, with the exception of those withheld for SABCS® press conferences, will be released approximately one month prior to the symposium. The abstracts withheld for press will be released at the beginning of the day on which the relevant press conference occurs.

Reporters, producers and editors agree to the embargoes and release times stated on the news releases, the news conference schedule and other materials. Failure to abide by the embargoes will result in suspension of credentials, which will affect attendance at the current and future symposia and ability to receive advance press materials.

By allowing an abstract to be included in the 2024 San Antonio Breast Cancer Symposium® media outreach program, the Presenter verifies that the abstract’s contents and its conclusions have not been and will not be published or presented in any form to the public before the start of the actual presentation. This includes, but is not limited to, non-embargoed press releases and interviews required by government agencies. Any release of material and specific non-embargoed information prior to the meeting’s embargo date as set forth by the SABCS® press office could result in exclusion from the official SABCS®​​​​​​​ press program.

Please see the media page for more information